Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Data From Clinical Study Of BioTheranostics Molecular Diagnostic Test Presented At American Society Of Clinical Oncology Annual Meeting
bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company"s THEROS CancerTYPE ID(R) molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially "unknown" using traditional diagnostics. Findings were presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl.
generic viagra online
Children With Fetal Alcohol Spectrum Disorders Have More Severe Behavioral Problems Than Those With ADHD
Children with fetal alcohol spectrum disorders (FASD) have a high risk of psychiatric problems, particularly attention deficit hyperactivity disorder (ADHD), conduct disorder, or both. Often children with FASD are initially diagnosed with ADHD. A new study is the first to examine a range of cognitive factors and social behavior in children with FASD and ADHD, finding that those with FASD have significantly weaker social cognition and facial emotion-processing abilities.
News of the day
Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced Her2-Positive Breast Cancer
Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says:
Endocrinology

St. Jude Medical Announces Australian TGA Regulatory Approval For Libra Deep Brain Stimulation Systems For Parkinson's Disease

St. Jude Medical, Inc. (NYSE:STJ) announced Australian Therapeutic Goods Administration (TGA) approval of its Libra® and LibraXP™ deep brain stimulation (DBS) systems for treating the symptoms of Parkinson"s disease, a neurological disorder that progressively diminishes a person"s control over his or her movements. Similar to a heart pacemaker, the Libra DBS systems function by delivering mild electrical pulses from an implanted device via thin wires with multiple independent electrodes. The stimulation is targeted to one of three regions in the brain which are involved in muscle control for the symptomatic treatment of Parkinson"s disease. "This approval is an important step forward in bringing our deep brain stimulation systems to a broader market," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to be able to provide physicians in Australia with these best-in-class deep brain stimulation systems, allowing them to have more capability and control in treating their patients." The Libra and LibraXP neurostimulators are constant current devices that feature the largest battery capacity of any DBS device in their class, which may maximize the time between device replacement procedures. This therapy can be externally programmed by a clinician to meet individual patient needs. An estimated 6.3 million people worldwide live with Parkinson"s disease, according to the European Parkinson"s Disease Association. The disease usually develops in people between the ages of 40 and 70, with an average age of onset of 60 years. Parkinson"s disease affects both men and women in almost equal numbers, although research suggests that men are two to three times more likely to be diagnosed with the disease than women. Parkinson"s Disease Symptoms Parkinson"s disease patients may experience stiffness or rigidity of the arms and legs, slowness or lack of movement, and walking difficulties, in addition to tremor of the hands, arms, legs, jaw or face. These symptoms can make simple, everyday tasks like getting dressed, shaving, eating with utensils and drinking from a glass difficult. Faced with these challenges, Parkinson"s disease patients often have a significant decline in their quality of life. In addition to the TGA approval, the Libra and LibraXP DBS systems have also received the CE Mark approval in Europe. In the U.S., the systems are currently being evaluated in clinical studies for depression, Parkinson"s disease and essential tremor. For more information about these studies, visit http://www.BROADENstudy.com, http://www.PowerOverPD.com and http://www.PowerOverET.com St. Jude Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009